In vitro aerosol deposition in the oropharyngeal region for staccato ® loxapine

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 4, 2010, Pages 253-260

  Dinh, Khe V ^a   Myers, Dan J ^a   Noymer, Peter D ^a   Cassella, James V ^a  

^a Alexza Pharmaceuticals   (United States)

Author keywords

aerosol; Alberta geometry; flow rate; inertial parameter; oropharyngeal deposition

Indexed keywords

LOXAPINE;

AEROSOL; AIRFLOW; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ENVIRONMENTAL TEMPERATURE; FLOW RATE; GEOMETRY; HUMIDITY; IN VITRO STUDY; OROPHARYNX; PARTICLE SIZE; VAPORIZATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIPSYCHOTIC AGENTS; COMPUTER SIMULATION; HUMANS; HUMIDITY; LOXAPINE; NEBULIZERS AND VAPORIZERS; OROPHARYNX; PARTICLE SIZE; RESPIRATORY MECHANICS; RHEOLOGY; TEMPERATURE;

EID: 77955444920     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0814     Document Type: Article

References (34)

1. Chan TL, and Lippmann M: Experimental measurements and empirical modeling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J. 190;41:399-409.
2. Emmett PC, Aitken JJ, and Hannan WJ: Measurements of the total and regional deposition of inhaled particles in the human respiratory tract. J Aerosol Sci. 1982;13:549-560.
3. Foord N, Black A, and Walsh M: Regional deposition of 2.5-7.5 mm diameter inhaled particles in healthy male nonsmokers. J Aerosol Sci.1978;9:343-357.
4. Bowes SM, and Swift DL: Deposition of inhaled particles in the oral airway during oronasal breathing. Aerosol Sci Technol. 1989;11:157-167.
5. Svartengren K, Lindestad PA, Svartengren M, Bylin G, Philipson K, and Camner P: Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J. 1994;7:1467-1473.
6. Borgström L, Bondesson E, Moré E, Trofast E, Newman SP: Lung deposition of budesonide inhaled via Turbuhaler-: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69-73.
7. Newman S, Pavia D, Garland N, and Clarke S: Effect of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis. 1982;119(Suppl):57-65.
8. Leach CL, Davidson PJ, and Boudreau JJ: Improved airway targeting with the CFC-free HFA-beclomethasone metereddose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353.
9. Newman S, Salmon A, Nave R, and Drollmann A: High lung deposition of 99mTc-labeled ciclesonide administered via HFAMDA to patients with asthma. Respir Med. 2006;100:375-384.
10. Borgström L, and Nilsson M: A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 1990;7:1068-1070.
11. Throsson L, Edsbäcker S, Kä llén A, and Löfdahl CG: Pharmacokinetics and systemic activity of fluticasone via Diskus- and pMDI, and of budesonide via Turbuhaler-. Br J Clin Pharmacol. 2001;52:529-538.
12. Stahlhofen W, Rudolf G, and James AC: Intercomparison of experimental regional aerosol deposition data. J Aerosol Med. 1989;2:285-308.
13. Lippmann M: Regional deposition of particles in the human respiratory tract. In: Lee DHK, Falk SD, Murphy SD, Geiger SR (eds). Handbook of Physiology-Reaction to Environmental Agents. American Physiological Society, Bethesda, MD, pp. 213-232, 1977.
14. Yu CP, Diu CK, and Soong TT: Statistical analysis of aerosol deposition in nose and mouth. Am Ind Hyg Assoc J. 1981; 42:726-733.
15. Swift LD: Apparatus and method for measuring regional distribution of therapeutic aerosols and comparing delivery systems. J Aerosol Sci.1992;23(Suppl 1):495-498.
16. Cheng KH, Yeh HC, and Swift DL: An experimental method for measuring aerosol deposition efficiency in the human oral airway. Am Ind Hyg Assoc J. 1997;58:207-213.
17. Cheng KH, Cheng YS, Yeh HC, and Swift DL: Measurements of airway dimensions and calculation of mass transfer characteristics of the human oral passage. J Biomed Eng. 1997;119:475-482.
18. Cheng YS, Zhou Y, and Chen TB: Particle deposition in a cast of human oral airways. Aerosol Sci and Technol. 1999;31:286-300.
19. Heenan, AF, Finlay WH, Matida EA, and Pollard A: Experimental measurements and computational modeling of the flow field in an idealized extrathoracic airway. J Aerosol Sci. 2003;39:572-591.
20. Zhang Y, Gilbertson K, and Finlay WH: In vivo-in vitro comparison of deposition in threemouth-throatmodelswithQvar and Turbuhaler inhalers. J AerosolMed. 2007;20:227-235.
21. DeHaan WH, and Finlay WH: In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J Aerosol Med. 2001;14:361-367.
22. DeHaan WH, and Finlay WH: Predicting extrathoracic deposition from dry powder inhalers. J Aerosol Sci. 2004;35:309-331.
23. Rahmatalla MF, Zuberbuhler PC, Lange CF, and Finlay WH: In vitro effect of a holding chamber on the mouth-throat deposition of QVAR- (Hydrofluoroalkane-Beclomethasone Dipropionate). J Aerosol Med. 2002;5:379-385.
24. Grgic B, Finlay WH, and Heenan AF: Regional aerosol deposition and flow measurements in an idealized mouth- throat. J Aerosol Sci. 2004;35:21-32.
25. Grgic B, Finlay WH, Burnell PKP, and Heenan AF: In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci. 2004;35: 1025-1040.
26. Rabinowitz JD, Wensley M, Lloyd P, Myers D, Shen W, Lu A, Hodges C, Hale R, Mufson D, and Zaffaroni A: Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther. 2004;309:769-775.
27. Hinds WC: Aerosol Technology: Properties, Behavior and Measurements of Airborne Particles. John Wiley & Sons, Inc., New York, 1999.
28. Stapleton KW, Guentsch E, Hoskinson MK, and Finlay WH: On the suitability of k-e turbulence modeling for aerosol deposition in the mouth and throat: a comparison experiment. J Aerosol Sci. 2000;6:739-749.
29. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
30. United States Pharmacopeia; USP-NF: Chapter 601: Physical Tests and Determinations. United States Pharmacopeia, Rockville, MD, 2008.
31. Tarsin W, Assi KH, and Chrystyn H: In-vitro intra- and interinhaler rate-dependent dosage emission from a combination of Budesonide and Eformoterol in a dry powder inhaler. J Aerosol Med. 2004;27:25-32.
32. Palander A, Mattila T, Karhu Mika, and Muttonen E: In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest. 2004;20:25-33.
33. Avram MJ, Spyker DA, Henthorn TK, and Cassella JV: The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009;85:71-77.
34. MacLeod D, Spyker DA, HoughtonW, Ikeda K, and Gan T: Pharmacokinetic profiles of fentanyl delivered by intravenous and inhaled thermal aerosol routes. Unpublished 2009